Long-term management of Malassezia spp dermatitis, a common pruritic skin disease in dogs, is focused on treating the underlying trigger and on topical therapy strategies. Acute episodes are commonly treated with oral antifungals. Terbinafine hydrochloride (TBF) does not use the fungal cytochrome P450 pathway, which may make it less vulnerable to drug interactions and side effects as compared with azole drugs. Because TBF is available as a low-cost generic formulation, it is an attractive alternative to azoles. In humans, TBF has been shown to concentrate and persist in skin.
Oral TBF doses >30 mg/kg q24h may be needed for efficacy in the treatment of canine Malassezia spp dermatitis.
Sign in to continue reading this article
Not registered? Create an account for free to read full articles on www.cliniciansbrief.com.